Clinical Outcomes after Mitral Valve Surgery in Failed MitraClip Procedures.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
04 2023
Historique:
medline: 7 4 2023
pubmed: 26 2 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

We retrospectively evaluated in-hospital and overall outcome of patients who received mitral valve replacement (MVR) after failed MitraClip procedure. A total of 26 out of 740 patients received MVR after treatment with MitraClip between June 2010 and December 2020. We analyzed in-hospital mortality and overall mortality during the median follow-up period of 72 days after MVR. The median age in the entire cohort was 77.5 years. In-hospital mortality was 15.4% ( The need for MVR for failed MitraClip repair is low and the results are acceptable. However, remaining options for reconstruction are usually limited and MVR is often needed. Anticipating success or failure according to the underlying pathology more than according to concomitant risk factors should form the basis in decision making for the treatment modality of first choice.

Sections du résumé

BACKGROUND
We retrospectively evaluated in-hospital and overall outcome of patients who received mitral valve replacement (MVR) after failed MitraClip procedure.
METHODS
A total of 26 out of 740 patients received MVR after treatment with MitraClip between June 2010 and December 2020. We analyzed in-hospital mortality and overall mortality during the median follow-up period of 72 days after MVR.
RESULTS
The median age in the entire cohort was 77.5 years. In-hospital mortality was 15.4% (
CONCLUSION
The need for MVR for failed MitraClip repair is low and the results are acceptable. However, remaining options for reconstruction are usually limited and MVR is often needed. Anticipating success or failure according to the underlying pathology more than according to concomitant risk factors should form the basis in decision making for the treatment modality of first choice.

Identifiants

pubmed: 35213930
doi: 10.1055/s-0042-1742757
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-170

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Clarence Pingpoh (C)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Maximillian Kreibich (M)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Tim Berger (T)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Martin Thoma (M)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Friedhelm Beyersdorf (F)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Thomas Comberg (T)

Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Department of Cardiology and Angiology II, University Heart Center Freiburg, Bad Krozingen, Germany.

Albi Fagu (A)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Matthias Siepe (M)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Martin Czerny (M)

Department of Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH